RxDoctor Payments Data

Edward Gaber, MD

Internal Medicine · Mandeville, LANPI 1962406298

Payments from drug & device makers

$6,435in general payments, 2019–2025

Across 428 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Lilly USA, LLC$586
  • Pfizer$488
  • Radius Health, Inc.$447
  • AbbVie$392
  • Novartis$353
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,32098%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,435 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$164,394
Medicare patients
542
Services billed
1,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide26$67,796
EliquisApixaban77$60,365
JardianceEmpagliflozin53$40,525
Repatha SureclickEvolocumab41$37,521
ProliaDenosumab15$25,475
FarxigaDapagliflozin Propanediol24$22,159
LinzessLinaclotide31$20,214
MounjaroTirzepatide17$19,137
MyrbetriqMirabegron21$17,484
CreonLipase/Protease/Amylase18$13,242
Ezetimibe779$13,127
TradjentaLinagliptin24$12,953
OzempicSemaglutide14$12,942
JanuviaSitagliptin Phosphate13$12,335
Rosuvastatin Calcium941$11,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$447$67,79626 claims
PfizerEliquis$488$60,36577 claims
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$95$55,58389 claims
AbbVieLinzess, Creon, Synthroid, Armour Thyroid$392$39,285138 claims
AmgenProlia$1,605$25,47515 claims
AstraZenecaFarxiga$343$22,15924 claims
Lilly USA, LLCMounjaro$586$19,13717 claims
Astellas Pharma US IncMyrbetriq$209$17,48421 claims
Novo NordiskOzempic$85$12,94214 claims
Sumitomo Pharma America, Inc.Gemtesa$126$8,72015 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$62$7,10218 claims
GSKArexvy$192$4,68315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →